论文部分内容阅读
盐酸喹那普利(quinapril hydrochloride,商品名Accupril,Parke-Davis公司产)作为一种给药1次/d的血管紧张素转移酶抑制剂已由美国食品与药物管理局批准用于高血压治疗。该药口服后至少60％被吸收,转变为一种具有活性的代谢物,quinaprilat和其它无活性的化合物。quillaprilat主要通过肾脏排泄,其消除半衰期约为2h,延长终末半衰期25h。采用喹那普利治疗的患者一般都能良好地耐受,其副反应
Quinapril hydrochloride (manufactured by Accupril, Parke-Davis) as an angiotensin-converting enzyme inhibitor administered once / d has been approved by the U.S. Food and Drug Administration for use in the treatment of hypertension . At least 60% of the drug is taken orally and converted to an active metabolite, quinaprilat and other inactive compounds. Quillaprilat is mainly excreted by the kidneys, with an elimination half-life of approximately 2 hours and an extended terminal half-life of 25 hours. Patients treated with quinapril are generally well tolerated with side effects